These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26911627)

  • 1. Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold.
    Lapteva L; Pariser AR
    J Investig Med; 2016 Feb; 64(2):376-82. PubMed ID: 26911627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology products.
    Manning ML; Thompson MD; Saber H; Maher VE; Crich JZ; Leighton JK
    Regul Toxicol Pharmacol; 2020 Feb; 110():104511. PubMed ID: 31678263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine INDs: review of clinical holds.
    Miller DL; Ross JJ
    Vaccine; 2005 Jan; 23(9):1099-101. PubMed ID: 15629351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
    Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
    Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-Year Experience for the Center for Drug Evaluation and Research, Part 2: FDA's Role in Ensuring Patient Safety.
    Jarow JP; Lemery S; Bugin K; Lowy N
    Ther Innov Regul Sci; 2017 Mar; 51(2):246-249. PubMed ID: 28553566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer.
    Senderowicz AM
    Clin Cancer Res; 2010 Mar; 16(6):1719-25. PubMed ID: 20215544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IND application.
    Ferkany JW; Williams M
    Curr Protoc Pharmacol; 2008 Sep; Chapter 9():Unit 9.10. PubMed ID: 22294234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative.
    Jarow JP; Casak S; Chuk M; Ehrlich LA; Khozin S
    Clin Cancer Res; 2016 May; 22(9):2111-3. PubMed ID: 26783289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory science: a special update from the United States Food and Drug Administration: Preclinical issues and status of investigation of botanical drug products in the United States.
    Wu KM; DeGeorge JG; Atrakchi A; Barry E; Bigger A; Chen C; Du T; Freed L; Geyer H; Goheer A; Jacobs A; Jean D; Rhee H; Osterberg R; Schmidt W; Farrelly JG
    Toxicol Lett; 2000 Jan; 111(3):199-202. PubMed ID: 10643863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
    Food and Drug Administration. HHS
    Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Analysis of Antibacterial Drug Development Trends in the United States, 1980-2019.
    Dheman N; Mahoney N; Cox EM; Farley JJ; Amini T; Lanthier ML
    Clin Infect Dis; 2021 Dec; 73(11):e4444-e4450. PubMed ID: 32584952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications.
    Karara AH; Edeki T; McLeod J; Tonelli AP; Wagner JA
    J Clin Pharmacol; 2010 Apr; 50(4):380-91. PubMed ID: 20097935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational new drug application; exception from informed consent; technical amendment--FDA. Final rule.
    Fed Regist; 1997 Jun; 62(115):32479. PubMed ID: 10169828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period.
    Jarow JP; Lemery S; Bugin K; Khozin S; Moscicki R
    Ther Innov Regul Sci; 2016 Nov; 50(6):705-709. PubMed ID: 27917324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding FDA regulatory requirements for investigational new drug applications for sponsor-investigators.
    Holbein ME
    J Investig Med; 2009 Aug; 57(6):688-94. PubMed ID: 19602987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substances doubtful for bulk drug substances list could be INDs.
    Thompson CA
    Am J Health Syst Pharm; 2016 Apr; 73(8):512-4. PubMed ID: 27045058
    [No Abstract]   [Full Text] [Related]  

  • 18. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 19. Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology.
    Shulman DS; Kiwinda LV; Edwards S; Clinton CM; Hunt S; Greenspan L; Lawler KD; Reaman G; Al-Sayegh H; Bona K; O'Neill AF; Shusterman S; Janeway KA; Place AE; Chi SN; Ma C; DuBois SG
    Cancer Med; 2021 Apr; 10(7):2310-2318. PubMed ID: 33751835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current regulatory perspectives on genotoxicity testing for botanical drug product development in the U.S.A.
    Wu KM; Dou J; Ghantous H; Chen S; Bigger A; Birnkrant D
    Regul Toxicol Pharmacol; 2010 Feb; 56(1):1-3. PubMed ID: 19782117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.